罗格列酮对2型糖尿病绝经后女性患者骨密度和骨转化指标的影响  

Effect of rosiglitazone on fractures and bone mineral density in postmenopausal women with type 2 diabetes

作　　者：程佳芬[1] 吴国亭[1] 

机构地区：[1]同济大学附属第十人民医院内分泌科,上海200072

出　　处：《同济大学学报（医学版）》2009年第6期46-49,共4页Journal of Tongji University(Medical Science)

基　　金：上海市科委生物医药处课题(07411963100)

摘　　要：目的评价罗格列酮对绝经后女性2型糖尿病患者骨密度和骨代谢标志物的影响。方法选取109例绝经后女性2型糖尿病患者,根据用药情况分为2组,分别为口服罗格列酮4 mg/d的罗格列酮组,以及不服用罗格列酮的对照组,分析入组患者用药前和用药1年后的骨密度值及骨代谢指标变化,前后两次结果对照并分别进行统计分析。结果罗格列酮组以及对照组用药后骨密度值均下降,其中,股骨颈骨密度下降值罗格列酮组明显大于对照组(P<0.05),其余部位骨密度下降值罗格列酮组与对照组相比无显著性差异(P>0.05)。罗格列酮治疗组Ⅰ型胶原表现明显的下降趋势,而骨钙素和PTH在TZD s治疗组与对照组比较无明显变化。所有入组病例在本研究观察病程中均无骨折事件报告。结论罗格列酮可能有潜在的致绝经后女性2型糖尿病患者骨质疏松性骨折的风险。Objective To determine whether rosiglitazone use was associated with the changes of bone mineral density （ BMD ） in post-menopausal women with type 2 diabetes. Methods A total of 109 cases of postmenopausal women with type 2 diabetes were randomly divided into 2 groups： the rosiglitazone-taking group in which every patient received 4 mg/d of rosiglitazone, and the control group. Analysis of bone mineral density and changes in bone metabolic markers was conducted and compared for statistical significance before and after an one-year study. Results After one year, BMD decreased in patients of both groups. Patients in the rosiglitazone-taking group were associated with greater bone loss in neck （ P 〈 0.05 ） , and demonstrated a clear downward trend of Collagen type I. No fracture was ever reported during the study course. Conclusion These observational results suggest that rosiglitazone may cause bone loss in postmenopausal women with type 2 diabetes mellitus. A randomized trial is warranted to test these results.

关 键 词：罗格列酮 2型糖尿病 绝经后女性 骨密度 

分 类 号：R58[医药卫生—内分泌]